Observational studyInternational journal of molecular sciences2026

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Lucienne Costa-Frossard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.